INDOAMIN
INDOAMIN
Each stock's 10,000-path forecast, rendered as light.
INDOAMIN (INDOAMIN) Stock Analysis & Case Study
Is INDOAMIN a good buy? The data-driven verdict.
INDOAMIN (INDOAMIN) trades at ₹143,on the numbers it worth a closer look, a Downstox Snapshot Score of 65/100.
On the numbers, INDOAMIN (INDOAMIN) worth a closer look, a Downstox Snapshot Score of 65/100, weighing inexpensive at 13.1× earnings, ROE of 22.4%, a 43% model probability of trading higher in a year. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 2027–2031.
Last updated . Data snapshot for research, not investment advice.
INDOAMIN fundamentals at a glance, PE, PB, ROE, ROCE, market cap, dividend yield
Is INDOAMIN overvalued? INDOAMIN P/E vs its sector
INDOAMIN's P/E of 13.1× sits below the sector peer median of 14.7×, so on earnings it screens cheaper than peers, while its 0.35% dividend yield is below the peer median of 1.65%.
INDOAMIN share price target 2027, 2028, 2029, 2030, 2031, a probability view
Unlike a single guessed number, this is a probability-weighted range from a 10,000-path Monte-Carlo simulation on 2.0y of INDOAMIN history (6%/yr drift, 52%/yr volatility).
| Year | Low (P10) | Median target (P50) | High (P90) | Upside vs today |
|---|---|---|---|---|
| INDOAMIN 2027 | ₹69 | ₹131 | ₹256 | -8% |
| INDOAMIN 2028 | ₹49 | ₹123 | ₹316 | -14% |
| INDOAMIN 2029 | ₹36 | ₹116 | ₹363 | -19% |
| INDOAMIN 2030 | ₹29 | ₹106 | ₹394 | -26% |
| INDOAMIN 2031 | ₹23 | ₹99 | ₹430 | -31% |
Median (P50) is the central estimate; the P10–P90 band is the 80% confidence range. Probabilities, not promises.
What is the probability INDOAMIN goes up, or doubles?
The bull case for INDOAMIN
- Trades at just 13.1× earnings, below the ~22× long-run Nifty average, so the valuation leaves room rather than pricing in perfection.
- High return on equity (22.4%), the business compounds shareholder capital efficiently, the hallmark of a quality franchise.
- Strong ROCE (19.9%) shows the core business earns well above its cost of capital.
- Upside scenario: the model's optimistic (P90) 3-year path reaches ₹363.
The bear case & risks
- The probability model is cautious 12 months out, only a 43% chance of finishing above today's price.
- High historical volatility (52%/yr) means a wide, bumpy range of outcomes, size positions accordingly.
- Downside scenario: the model's pessimistic (P10) 3-year path falls to ₹36.
INDOAMIN volatility & expected range, how bumpy is the ride?
Over the last 2.0 years INDOAMIN compounded at 6%/year with annualized volatility of 52%. That volatility implies a 1-year 80% range of ₹69–₹256, the honest backbone behind any single price target.
INDOAMIN price forecast, the full 60-month probability fan
INDOAMIN price probability fan
Each band shows where 10,000 simulated paths land. The wider the fan, the more uncertainty.
Probability of key outcomes
What are the odds INDOAMIN hits common targets within the simulated horizon?
Full multi-horizon detail on the INDOAMIN price target & forecast page.
INDOAMIN Piotroski F-Score: 4/9, how financially strong is it?
The Piotroski F-Score grades financial strength on nine profitability, leverage and efficiency checks. INDOAMIN scores 4/9,mixed financial health.
INDOAMIN MTF margin & leverage, Upstox, Zerodha, Groww, Dhan
Margin Trading Facility lets you buy INDOAMIN with part of the capital. Lower margin % = higher leverage. Rates compared across brokers (no competitor publishes this):
| Broker | Margin required | Approx. leverage |
|---|---|---|
| ZerodhaCHEAPEST | 50.0% | 2.0× |
Compare every broker on the INDOAMIN MTF page.
INDOAMIN vs peers,sector comparison
About INDOAMIN: sector, index & market-cap context
INDOAMIN (INDOAMIN) is a small-cap NSE-listed company, and a constituent of the Nifty 500 index group, with a market capitalisation of ₹1,041 Cr. See more Nifty 500 stocks.
How the INDOAMIN Snapshot Score & forecast are built
The Downstox Snapshot Score is a transparent, rules-based read of INDOAMIN's public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.
This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.
INDOAMIN analysis, FAQs
Is INDOAMIN (INDOAMIN) a good buy?
On the numbers, INDOAMIN (INDOAMIN) worth a closer look, a Downstox Snapshot Score of 65/100, weighing inexpensive at 13.1× earnings, ROE of 22.4%, a 43% model probability of trading higher in a year. This is a data snapshot for research, not investment advice.
Is INDOAMIN overvalued or undervalued?
INDOAMIN trades at 13.1× earnings versus a peer median of 14.7×, so it screens cheaper than its sector peers.
What is the INDOAMIN share price target for 2031?
INDOAMIN's probability-weighted 2031 median target is ₹99, with an 80% range of ₹23–₹430 (10,000-path Monte-Carlo).
What is the probability INDOAMIN doubles in 5 years?
The modelled probability of INDOAMIN reaching ₹287 (2×) within 5 years is 17%.
What is the bull case for INDOAMIN?
Trades at just 13.1× earnings, below the ~22× long-run Nifty average, so the valuation leaves room rather than pricing in perfection. High return on equity (22.4%), the business compounds shareholder capital efficiently, the hallmark of a quality franchise. Strong ROCE (19.9%) shows the core business earns well above its cost of capital.
What are the risks in INDOAMIN?
The probability model is cautious 12 months out, only a 43% chance of finishing above today's price. High historical volatility (52%/yr) means a wide, bumpy range of outcomes, size positions accordingly.